enzalutamide

June 11, 2020June 11, 2020

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

News

Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a Phase ... Read more

June 4, 2020June 4, 2020

NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic

News

Urged by Prostate Cancer UK, NHS England is making Xtandi (enzalutamide) and Zytiga (abiraterone acetate) available during the COVID-19 pandemic for men with newly diagnosed advanced prostate cancer. Access to ... Read more

January 28, 2020February 3, 2020

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer

News

A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 — which inhibits the glucocorticoid receptor — is able to overcome prostate cancer resistance to Xtandi ... Read more

December 18, 2019December 18, 2019

FDA Expands Xtandi Approval to Include Metastatic Castration-sensitive Prostate Cancers

News

The U.S. Food and Drug Administration (FDA) has agreed to expand Xtandi‘s (enzalutamide) approval to include men whose metastatic prostate cancer still responds to hormone therapy, Astellas Pharma and Pfizer, the treatment’s developers, announced. ... Read more

August 26, 2019

Request for Xtandi to Treat Metastatic Hormone-sensitive Prostate Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has agreed to review Astellas Pharma and Pfizer‘s application for Xtandi (enzalutamide), requesting its approved use be expanded to include men whose metastatic prostate ... Read more

August 5, 2019

Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says

News

Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase 3 ... Read more

July 3, 2019

Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says

News

Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, ... Read more

May 22, 2019May 22, 2019

Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows

News

Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. ... Read more

May 16, 2019

Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests

News

Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were ... Read more

March 4, 2019March 4, 2019

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

News

African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans diagnosed ... Read more